Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Mangoceuticals, Inc. Common Stock (MGRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MGRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 0.31% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.41M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.76 | 52 Weeks Range 1.32 - 7.05 | Updated Date 06/29/2025 |
52 Weeks Range 1.32 - 7.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3141.81% |
Management Effectiveness
Return on Assets (TTM) -53.56% | Return on Equity (TTM) -115.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18386227 | Price to Sales(TTM) 36.03 |
Enterprise Value 18386227 | Price to Sales(TTM) 36.03 | ||
Enterprise Value to Revenue 35.98 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 10644500 | Shares Floating 8117841 |
Shares Outstanding 10644500 | Shares Floating 8117841 | ||
Percent Insiders 27.82 | Percent Institutions 0.66 |
Upturn AI SWOT
Mangoceuticals, Inc. Common Stock
Company Overview
History and Background
Mangoceuticals, Inc. was founded in 2022 and is focused on developing, marketing, and selling products that improve men's health and wellness. The company went public via IPO in 2023.
Core Business Areas
- Pharmaceuticals: Focuses on developing and marketing prescription medication to treat erectile dysfunction.
- Telehealth: Offers online consultations and prescriptions for men's health products.
- Wellness Products: May include supplementary products related to men's sexual health and wellness.
Leadership and Structure
Jacob D. Cohen serves as the CEO. Organizational structure is typical of an early-stage public company.
Top Products and Market Share
Key Offerings
- Mango: A prescription medication to treat erectile dysfunction sold through a telehealth platform. Market share is currently small as they are a new player. Competitors include Viagra (Pfizer), Cialis (Eli Lilly), and generic ED medications.
Market Dynamics
Industry Overview
The men's health market is large and growing, driven by factors such as an aging population and increased awareness of health issues. The telehealth segment is also experiencing rapid growth.
Positioning
Mangoceuticals is a relatively new player attempting to disrupt the market with its telehealth-based approach and targeted product offerings. Its competitive advantage is its branding and focus on a specific niche.
Total Addressable Market (TAM)
The global erectile dysfunction market size was valued at $3.3 billion in 2022 and is projected to reach $5.9 billion by 2032. Mangoceuticals aims to capture a portion of this market through their telehealth model, focusing initially on specific demographics.
Upturn SWOT Analysis
Strengths
- Telehealth platform offering convenience and privacy
- Targeted marketing towards a specific demographic
- Focus on men's sexual health and wellness
Weaknesses
- Limited product portfolio
- Small market share compared to established players
- Dependence on single product line
Opportunities
- Expanding product offerings to related men's health issues
- Increasing brand awareness and marketing reach
- Partnerships with other telehealth providers
Threats
- Competition from established pharmaceutical companies
- Regulatory changes affecting telehealth and prescription medications
- Generic competition and pricing pressures
Competitors and Market Share
Key Competitors
- PFE
- LLY
Competitive Landscape
Mangoceuticals faces significant competition from established pharmaceutical giants with well-known brands and extensive resources. Mangoceuticals must focus on differentiating itself through its telehealth approach and targeted marketing to gain market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent establishment.
Future Projections: Analyst estimates not available. Future growth depends on marketing success, product expansion, and regulatory landscape.
Recent Initiatives: Initiatives are focused on building its telehealth platform and marketing its initial product.
Summary
Mangoceuticals is a new company targeting the men's health market with a telehealth-based approach. It has the potential to disrupt the market, but faces significant competition from established players. The company's success will depend on its ability to build brand awareness, expand its product offerings, and navigate the regulatory landscape. The limited track record is a substantial risk, but focused marketing may prove advantageous.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on limited available information and should not be considered investment advice. Data may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mangoceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2023-03-21 | Co-Founder, CEO & Chairman Mr. Jacob D. Cohen | ||
Sector Healthcare | Industry Health Information Services | Full time employees 3 | Website https://www.mangoceuticals.com |
Full time employees 3 | Website https://www.mangoceuticals.com | ||
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.